Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

Abstract

We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against <i>Aspergillus</i>. Clinicians should be aware of potential <i>Aspergillus</i> infections in patients treated with this drug.